SCHEMBL6788939

SCHEMBL6788939

NC(=O)CCCN1CCC(c2ccc3ccccc3c2O)CC1

nearest known ligand 0.50

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.50
SLC6A4 P31645 2/20 0.50
HTR1D P28221 1/20 0.46
HTR1B P28222 1/20 0.46
HTR7 P34969 4/20 0.45
HRH3 Q9Y5N1 1/20 0.44
DRD4 P21917 2/20 0.43
ADRA1D P25100 2/20 0.42
GAA P10253 1/20 0.42
PKM P14618 1/20 0.42
HIF1A Q16665 1/20 0.42
NR1H4 Q96RI1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6784657 0.85 SLC6A4 (0.57) DRD2SLC6A4HTR7HRH3ADRA1D
SCHEMBL6724395 0.84 DRD2 (0.49) DRD2SLC6A4HTR1DHTR1BHTR7
SCHEMBL6795939 0.81 DRD2 (0.51) DRD2SLC6A4HTR1DHTR1BHRH3
SCHEMBL6710692 0.81 DRD2 (0.49) DRD2SLC6A4HTR7ADRA1D
SCHEMBL6789557 0.80 DRD2 (0.42) DRD2SLC6A4HTR1DHTR1BHTR7
SCHEMBL7957074 0.78 DRD2 (0.58) DRD2SLC6A4HTR1DHTR1BHTR7
SCHEMBL6784248 0.77 MTNR1A (0.44) DRD2SLC6A4HRH3
SCHEMBL3122425 0.76 DRD2 (0.66) DRD2SLC6A4HTR7ADRA1D
SCHEMBL3111720 0.76 HRH3 (0.50) DRD2HTR7HRH3DRD4
SCHEMBL3115404 0.76 DRD2 (0.51) DRD2SLC6A4HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147557-A1 Aryl piperidine derivatives as inducers of ldl-receptor expression BOUILLOT ANNE (FR) 2004-07-29 US claimed
EP-1351937-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION GLAXO GROUP LIMITED (GB) 2003-10-15 EP claimed
WO-2002055497-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION GLAXO GROUP LIMITED (GB) 2002-07-18 WO claimed
US-20040147557-A1 Aryl piperidine derivatives as inducers of ldl-receptor expression BOUILLOT ANNE (FR) 2004-07-29 US disclosed
US-20040072865-A1 Aryl piperidine derivatives as inducers of ldl-receptor expression SMITHKLINE BEECHAM CORPORATION 2004-04-15 US disclosed
EP-1351935-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION GLAXO GROUP LIMITED (GB) 2003-10-15 EP disclosed
EP-1351937-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION GLAXO GROUP LIMITED (GB) 2003-10-15 EP disclosed
WO-2002055497-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION GLAXO GROUP LIMITED (GB) 2002-07-18 WO disclosed
WO-2002055495-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION GLAXO GROUP LIMITED (GB) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147557-A1 Aryl piperidine derivatives as inducers of ldl-receptor expression NR1H2, NR1H3, NR1H4 DRD2 152/4885SLC6A4 969/4885HTR1D 83/4885
US-20040072865-A1 Aryl piperidine derivatives as inducers of ldl-receptor expression NR1H2, NR1H3, NR1H4 DRD2 269/4885SLC6A4 812/4885HTR1D 142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.